Oncology Central

Redirection of T-cell effector functions for cancer therapy: bispecific antibodies and chimeric antigen receptors

0

T cells are the most potent cells of the immune system; however, they fail in the immunosurveillance of tumors. In previous decades, scientists began studying methods to take advantage of T-cell potency in cancer therapy by redirecting them against tumors independently from the T-cell receptor-defined specificity. Among different approaches, the most promising are the use of bispecific antibodies and T-cell engineering to create chimeric antigen receptors.

To view restricted content, please:
Share:

Leave A Comment